Leapcure recruited 44% of all enrolled patients in a completed Phase 3 Atopic Dermatitis study, through a multi-channel engine.

Moderate-to-severe AD recruitment, where broad campaigns miss. We pre-screen and educate patients against the protocol's criteria, so your sites receive enrollment-ready candidates, not referrals that create coordinator work.

Talk to our AD teamSee how it works →
58
Patients enrolled by Leapcure
221
Patients scheduled for ICF (pre-screened and educated)
22
Active sites with Leapcure enrollments
3
Countries enrolled (US, Poland, Germany)

Understanding Atopic Dermatitis as a Clinical Trial Indication

Atopic dermatitis affects roughly 1 in 10 adults, but moderate-to-severe disease, the population most trials require, is a far narrower group. Eligibility turns on a stack of overlapping thresholds: body surface area involvement, EASI and IGA severity scores, itch (NRS) ratings, and daily symptom-diary compliance. Most people who raise their hand will not clear all of them, so screen-fail rates run high before a single patient is randomized.

Atopic dermatitis is also one of dermatology's most actively recruited indications, which means many trials compete for the same narrow pool at the same time. Washout and treatment-history rules exclude patients already on systemic therapy or recent biologics, and placebo-controlled designs make some patients hesitant to enroll at all. Broad digital advertising reaches volume, but it rarely reaches the eligible, motivated patient efficiently.

Leapcure recruits for moderate-to-severe AD through a multi-channel engine: precision digital as the primary driver, supported by eczema and dermatitis advocacy communities and a patient-support model that carries candidates through pre-screening. In a completed Phase 3 moderate-to-severe AD program across the US, Poland, and Germany, that approach delivered 58 enrolled patients, 44% of the entire study, and finished enrollment in roughly 12 months against an industry-average Phase 3 recruitment period of about 18 months.

The Challenge

Moderate-to-severe AD recruitment demands more than reach. It demands the right pool, found efficiently.

A narrow moderate-to-severe criteria drives screen failure before enrollment begins

Moderate-to-severe AD eligibility turns on overlapping thresholds: body surface area, EASI and IGA severity, itch (NRS) ratings, and daily symptom-diary completion. Most patients who express interest miss at least one criterion. Recruitment that passes unscreened interest straight to sites inflates screen-fail rates and burns coordinator time on candidates who were never going to qualify.

Leapcure pre-screens against the protocol's criteria before any referral. In a completed Phase 3 AD program, 221 patients were pre-screened and educated before site assignment, and 58 went on to enroll.

Broad digital spend is expensive and inefficient in a crowded AD field

Atopic dermatitis is one of dermatology's most actively recruited indications, so multiple trials chase the same narrow pool at once. Buying volume through broad advertising drives cost per enrolled patient up fast, without guaranteeing the eligible, motivated candidates a protocol actually needs.

In a completed Phase 3 AD program, Leapcure's multi-channel mix delivered a blended enrollment acquisition cost of $2,260, against a sponsor-reported industry benchmark of $117,819, and an estimated $3.9M in global savings. (Acquisition cost varies by protocol, phase, site selection, and channel mix.)

Multi-country AD trials stall when site engagement is inconsistent

Moderate-to-severe AD trials are typically multinational, and site capacity, patient access, and referral patterns vary widely between regions. When one country falls behind, timelines slip. When several do, the program is at risk.

In a completed Phase 3 AD program, Leapcure maintained active enrollment across the US, Poland, and Germany at once, rebalancing channel mix and site support weekly per region.

Washout rules and placebo concerns keep eligible patients from enrolling

Even patients who meet the severity criteria can be lost at the doorstep. Washout and treatment-history requirements exclude many already on systemic therapy, and placebo-controlled designs make some patients reluctant to risk months without active treatment. Without education and support, these patients quietly drop out of the funnel.

Leapcure's patient-support team explains washout, study design, and what participation involves before referral, so the patients who reach your sites understand the trial and have chosen to move forward.

Three Channels. One Multi-Channel Engine for Your AD Trial.

Every moderate-to-severe AD study is different. Leapcure deploys the right mix of precision digital, eczema and dermatitis advocacy communities, and patient support, mapped to your protocol, your sites, your geographies, and your timeline.

1

Activate the right multi-channel mix for your AD protocol

Leapcure activates precision digital as the primary engine (search, social, and condition-specific community placements optimized for moderate-to-severe AD), supported by eczema and dermatitis advocacy communities and a patient-support model that keeps candidates engaged through enrollment. The mix is calibrated to your protocol, site locations, and eligibility criteria, not applied uniformly.

2

Pre-screen and educate against the criteria

Every patient is engaged by Leapcure's team before site assignment. We assess the protocol's eligibility thresholds, including BSA, EASI, IGA, NRS, and diary requirements, explain washout and study design, and confirm patients understand and want to proceed. Sites conduct official screening; Leapcure ensures the patients who arrive are informed and prepared.

3

Optimize in real time against site capacity

Channel performance and site contact rates are tracked continuously across regions. Digital, advocacy, and patient-support contributions are rebalanced based on referral quality, site intake capacity, and protocol progress. In the completed Phase 3 AD program, this approach delivered 58 enrolled patients, 44% of the study, and finished enrollment in roughly 12 months.

Phase 3 Moderate-to-Severe Atopic Dermatitis Recruitment, Completed. 44% of the Study, Delivered by Leapcure.

Challenge Context

Indication

Moderate-to-severe atopic dermatitis, Phase 3

Sites

22 active sites with Leapcure enrollments across the US, Poland, and Germany

Challenge

Narrow moderate-to-severe criteria (BSA, EASI, IGA, NRS, diary compliance); high screen-fail risk; washout and treatment-history exclusions; placebo-controlled design; dispersed multi-country population; a crowded AD recruitment field.

Channels deployed

Precision digital as the primary engine, supported by eczema and dermatitis advocacy communities (The Mighty, National Eczema Association, Eczema Blues, DermNet NZ) and a patient-support model coordinated across 3 countries.

Results & Metrics

Patients enrolled

58 patients enrolled by Leapcure, 44% of all participants in the study.

Funnel

221 patients pre-screened, educated, and scheduled for ICF before site assignment; approximately 23:1 referral-to-randomized ratio, reflecting the protocol's strict eligibility.

Enrollment speed

Enrollment completed in roughly 12 months, faster than the approximately 18-month average recruitment period for industry-sponsored Phase 3 trials.

Cost efficiency

$2,260 blended enrollment acquisition cost vs. a sponsor-reported industry benchmark of $117,819, and an estimated $3.9M in global savings. Acquisition cost varies by protocol, phase, site selection, and channel mix.

Advocacy contribution

Roughly 10% of enrollments came through patient advocacy group campaigns; precision digital drove the majority.

Patient quality

Pre-screened, educated candidates arrived ready for official site screening, reducing coordinator burden and screen-fail rates relative to broad digital recruitment.

Sponsor attribution

Leading Dermatology Sponsor, Phase 3 Atopic Dermatitis

Four Channels. Built for Atopic Dermatitis. Active Before Your Trial Opens.

Leapcure reaches moderate-to-severe AD patients through precision digital as the primary engine, eczema and dermatitis advocacy communities, a patient-support model, and a fourth capability most recruitment vendors do not offer: AEO and AI-search visibility delivered to your trial.

Precision Digital Campaigns (primary engine)

  • •Search, social, and condition-specific community placements optimized for moderate-to-severe AD, targeted by geography, severity signals, and site proximity.
  • •Digital is mapped to site capacity in real time across regions, so referrals are modulated and sites are not overwhelmed.
  • •In a completed Phase 3 AD program, precision digital drove the majority of qualified referrals at a blended enrollment acquisition cost well below the sponsor-reported industry benchmark.

Eczema and Dermatitis Advocacy Communities

  • •Named AD community partners including The Mighty, the National Eczema Association, Eczema Blues, and DermNet NZ.
  • •Content co-developed with community partners positions research as a trusted option, not an unsolicited pitch.
  • •For AD, advocacy is a supporting trust channel (roughly 10% of enrollment in our last Phase 3), not the whole strategy.

Patient Support Model

  • •Every referred patient receives step-by-step guidance from first contact through enrollment, including help understanding washout, study design, and visit burden.
  • •Caregivers and family members are included where relevant.
  • •Patient support is why sites receive enrollment-ready candidates, not referrals that create coordinator work.

AEO and AI-Search Visibility for Your Trial

  • •Patients increasingly ask ChatGPT, Perplexity, and Google's AI Overview questions like 'what atopic dermatitis trials am I eligible for?' Leapcure makes your trial's information genuinely retrievable by these engines.
  • •That means crawlable, server-rendered content with clear answer passages, unique first-party data, cited sources, and presence in the third-party communities AI engines actually cite. It is good content structure plus real authority, not schema tricks or 'AI markup.'
  • •As AI search grows as a patient-discovery path, this channel compounds over the life of your study.

Built on Real Relationships in the Eczema and Dermatitis Community

Leapcure's AD community partnerships are active, named, and co-developed, not list purchases.

The Mighty

Large patient media platform; broad reach into the eczema and chronic-condition community.

National Eczema Association

Leading US eczema patient organization; clinical credibility anchor for AD.

Eczema Blues

Patient-founded eczema community and content platform; trusted peer voice.

DermNet NZ

Widely referenced dermatology information resource; authority signal across skin conditions.

Living with eczema or atopic dermatitis? A clinical trial may be an option.

If you are living with moderate-to-severe atopic dermatitis, a clinical trial may give you access to investigational treatments not yet widely available. We know that managing flares, itch, and daily skin care can be exhausting, and that researching trial options on top of that is a lot. Leapcure's team offers step-by-step support, and we include your family or caregivers wherever that helps.

See if an AD trial may be right for you
Leapcure kangaroo mascot

Leapcure's atopic dermatitis recruitment team has completed a Phase 3 moderate-to-severe AD program, enrolling 58 patients (44% of the entire study) across the US, Poland, and Germany, at a fraction of the sponsor-reported industry benchmark for acquisition cost. We deploy precision digital, eczema and dermatitis advocacy communities, patient support, and AEO channels adapted to your protocol, and we can mobilize within 48 hours of program launch.

Talk to our AD team